COLGATE PALMOLIVE CO CL

Healthcare SIC 2844 - Perfumes, Cosmetics & Other Toilet Preparations NYSE

Colgate-Palmolive Company (together with its subsidiaries, "we," "us," "our," the "Company" or "Colgate-Palmolive") is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. To achieve our business and financial objectives and deliver peer-leading performance and total shareholder return, we are focused on driving organic sales growth; delivering consistent, compounded earnings per share growth; achieving operational efficiencies; and driving growth in free cash flow along with the efficient use of our balance sheet. We do this by leveraging the global reach and penetration of our brands; building the incremental benefit of superior, science-based innovation supported by an agile and resilient supply chain; harnessing the power of best-in-class omni-channel demand generation; leading in capabilities such as data, analytics and artificial intelligence ("AI"); and evolving our high-impact, inclusive culture. Our products are marketed in over 200 countries and territories throughout the world. Colgate-Palmolive was founded in 1806 and incorporated under the laws of the State of Delaware in 1923.

Last close 88.77 2026-09-04
Market cap $70.77B 2026-06-30 share count
52-week range 74.55 - 99.33

Valuation FY2025 figures against the last close

P/S3.5x
P/E33.8x
P/FCF19.5x
EV/EBITDA19.7x
Dividend yield
Diluted EPS2.63

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $20.38B$20.10B$19.46B$17.97B$17.42B$16.47B$15.69B$15.54B$15.45B$15.20B
Cost of revenue $8.13B$7.94B$8.13B$7.72B$7.05B$6.45B$6.37B$6.31B$6.17B$6.07B
Gross profit $12.25B$12.16B$11.33B$10.25B$10.38B$10.02B$9.32B$9.23B$9.28B$9.12B
R&D $366.0M$355.0M$343.0M$320.0M$307.0M$290.0M$281.0M$277.0M$285.0M$289.0M
SG&A $7.90B$7.73B$7.15B$6.57B$6.41B$6.02B$5.58B$5.39B$5.40B$5.14B
Operating income $3.31B$4.27B$3.98B$2.89B$3.33B$3.88B$3.55B$3.69B$3.71B$3.96B
Interest expense $267.0M$292.0M$287.0M$167.0M
Pre-tax income $3.06B$3.96B$3.39B$2.66B$3.09B$3.65B$3.30B$3.46B$3.49B$3.74B
Income tax $798.0M$907.0M$937.0M$693.0M$749.0M$787.0M$774.0M$906.0M$1.31B$1.15B
Net income $2.13B$2.89B$2.30B$1.78B$2.17B$2.69B$2.37B$2.40B$2.02B$2.44B
EPS, basic 2.643.532.782.132.563.152.762.762.302.74
EPS, diluted 2.633.512.772.132.553.142.752.752.282.72
Shares, diluted (wtd. avg.) $811.1M$823.2M$829.2M$838.8M$848.3M$859.3M$861.1M$873.0M$887.8M$898.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.29B$1.10B$966.0M$775.0M$832.0M$888.0M$883.0M$726.0M$1.53B$1.31B
Short-term investments $107.0M$160.0M$179.0M
Receivables $1.68B$1.52B$1.59B$1.50B$1.30B$1.26B$1.44B$1.40B$1.48B$1.41B
Inventory $2.03B$1.99B$1.93B$2.07B$1.69B$1.67B$1.40B$1.25B$1.22B$1.17B
Total current assets $5.71B$5.32B$5.28B$5.11B$4.40B$4.34B$4.18B$3.79B$4.64B$4.34B
Property, plant and equipment $4.66B$4.42B$4.58B$4.31B$3.73B$3.72B$3.75B$3.88B$4.07B$3.84B
Goodwill $3.12B$3.27B$3.41B$3.35B$3.28B$3.82B$3.51B$2.53B$2.22B$2.11B
Other intangibles $1.54B$1.76B$1.89B$1.92B$2.46B$2.89B$2.67B$1.64B$1.34B$1.31B
Total assets $16.33B$16.05B$16.39B$15.73B$15.04B$15.92B$15.03B$12.16B$12.68B$12.12B
Accounts payable $2.09B$1.80B$1.70B$1.55B$1.48B$1.39B$1.24B$1.22B$1.21B$1.12B
Short-term debt $1.11B$652.0M$20.0M$14.0M$12.0M$9.0M$254.0M$0$0$0
Total current liabilities $6.85B$5.76B$4.74B$4.00B$4.05B$4.40B$4.04B$3.34B$3.41B$3.31B
Long-term debt $6.87B$7.29B$8.22B$8.74B$7.19B$7.33B$7.33B$6.35B$6.57B$6.52B
Total liabilities $15.96B$15.50B$15.44B$14.93B$14.07B$14.82B$14.48B$11.96B$12.43B$12.11B
Retained earnings $26.59B$26.14B$25.29B$24.57B$24.35B$23.70B$22.50B$21.61B$20.53B$19.92B
Total equity $54.0M$212.0M$609.0M$401.0M$609.0M$743.0M$117.0M-$102.0M-$60.0M-$243.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $4.20B$4.11B$3.75B$2.56B$3.33B$3.72B$3.13B$3.06B$3.05B$3.14B
Depreciation and amortisation $630.0M$605.0M$567.0M$545.0M$556.0M$539.0M$519.0M$511.0M$475.0M$443.0M
Stock-based compensation $155.0M$135.0M$122.0M$125.0M$135.0M$107.0M$100.0M$109.0M$127.0M$123.0M
Capital expenditure $564.0M$561.0M$705.0M$696.0M$567.0M$409.0M$335.0M$436.0M$553.0M$593.0M
Investing cash flow -$817.0M-$534.0M-$742.0M-$1.60B-$592.0M-$779.0M-$2.10B-$1.17B-$471.0M-$499.0M
Financing cash flow -$3.26B-$3.39B-$2.79B-$952.0M-$2.77B-$2.92B-$870.0M-$2.68B-$2.45B-$2.23B
Buybacks $1.21B$1.74B$1.13B$1.31B$1.32B$1.48B$1.20B$1.24B$1.40B$1.33B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000021665-26-000006.

Others in SIC 2844

TickerCompanyMarket capP/ERevenue growth
EL ESTEE LAUDER COMPANIES INC $37.63B 207.7x 5.0%
KVUE Kenvue Inc. $36.00B 24.7x -2.1%
ELF e.l.f. Beauty, Inc. $6.47B 249.2x 24.6%
IPAR INTERPARFUMS INC $3.74B 22.3x 2.5%
COTY COTY INC. $2.58B -1.5%
EPC EDGEWELL PERSONAL CARE Co $1.33B 54.5x -1.3%
WALD Waldencast plc $156.3M -0.7%
SLSN SOLESENCE, INC. $60.0M 42.5x 18.6%